Evidence map›Paper›PMID 28289069›Full record

ReviewCirculation2017

Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association.

David S Siscovick, Thomas A Barringer, Amanda M Fretts, Jason H Y Wu, Alice H Lichtenstein, Rebecca B Costello, Penny M Kris-Etherton, Terry A Jacobson, Mary B Engler, Heather M Alger and 3 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Circulation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 266 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
266citing papers in PubMed, 15 pooled it
51.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

266 citing papers in PubMed, 15 syntheses or guidelines pooled it, 619 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Trial
  18. SynbioticNutrients · 2024
    Trial
  19. Trial
  20. Trial

206 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

David S Siscovick
Thomas A Barringer
Amanda M Fretts
Jason H Y Wu
Alice H Lichtenstein
Rebecca B Costello
Penny M Kris-Etherton
Terry A Jacobson
Mary B Engler
Heather M Alger
Lawrence J Appel
Dariush Mozaffarian
American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology
American Heart Association · USSchrodinger (United States) · US

Funding

Fatty Acids and Major Cardiovascular OutcomesR01HL085710 · NHLBI · TUFTS UNIVERSITY BOSTON · PI MOZAFFARIAN, DARIUSH · 2006 to 2016
$5.1M
Diet Quality and CVD Risk Factors in a Family Based Weight Management StudyR01HL101236 · NHLBI · TUFTS UNIVERSITY BOSTON · PI LICHTENSTEIN, ALICE H · 2010 to 2013
$1.4M
NHLBI NIH HHS R01 HL085710NHLBI NIH HHS R01 HL101236
6 · The paper itself

Abstract

Multiple randomized controlled trials (RCTs) have assessed the effects of supplementation with eicosapentaenoic acid plus docosahexaenoic acid (omega-3 polyunsaturated fatty acids, commonly called fish oils) on the occurrence of clinical cardiovascular diseases. Although the effects of supplementation for the primary prevention of clinical cardiovascular events in the general population have not been examined, RCTs have assessed the role of supplementation in secondary prevention among patients with diabetes mellitus and prediabetes, patients at high risk of cardiovascular disease, and those with prevalent coronary heart disease. In this scientific advisory, we take a clinical approach and focus on common indications for omega-3 polyunsaturated fatty acid supplements related to the prevention of clinical cardiovascular events. We limited the scope of our review to large RCTs of supplementation with major clinical cardiovascular disease end points; meta-analyses were considered secondarily. We discuss the features of available RCTs and provide the rationale for our recommendations. We then use existing American Heart Association criteria to assess the strength of the recommendation and the level of evidence. On the basis of our review of the cumulative evidence from RCTs designed to assess the effect of omega-3 polyunsaturated fatty acid supplementation on clinical cardiovascular events, we update prior recommendations for patients with prevalent coronary heart disease, and we offer recommendations, when data are available, for patients with other clinical indications, including patients with diabetes mellitus and prediabetes and those with high risk of cardiovascular disease, stroke, heart failure, and atrial fibrillation.

Indexed as

Dietary SupplementsAtrial FibrillationCardiac Surgical ProceduresCardiovascular DiseasesDiabetes ComplicationsDiabetes MellitusFatty Acids, Omega-3Fish OilsHeart FailureHumansPrimary PreventionRiskSecondary PreventionStrokeFatty Acids, Omega-3Fish OilsAHA Scientific Statementscardiovascular diseasefatty acids, omega-3fish oilsprevention and controlrandomized controlled trials

Identifiers

PMID28289069
PMCPMC6903779
OpenAlexW2597054569

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.